 |
Pharmaceutical Strategic Outlook
April 11, 2012—April 13, 2012
New York, New York
2012 PDA Annual Meeting
April 16, 2012—April 18, 2012
Phoenix, Arizona
World Congress of Cardiology
April 18, 2012—April 21, 2012
Dubai, United Arab Emirates
10th EGA International Symposium on Biosimilar Medicines
April 19, 2012—April 20, 2012
London, United Kingdom
LogiPharma
April 24, 2012—April 26, 2012
Geneva, Switzerland 
|
|
|
 |
 |
 Mass spectrometer measures dissolved gases and vapors
The HPR-40 Membrane Inlet Mass Spectrometer from Hiden Analytical has a new range of flow-through, semi-permeable interfaces designed to measure dissolved gases and vapors in liquid media that flows across or against the membrane surface. Interfaces designed for specific applications are continually being developed as needs arise. The HPR-40 can be used with flowing samples (using the circular membrane inlet), with single static samples (using the single probe membrane interface), or for multistream sampling (using 4-, 8-, 20-, 40-, and 80-way selectors). The HPR-40 benchtop system includes control and data analysis programs, and multistream samplers have automated, user-programmable sequencing. |
|
|
 |
|
Amgen and AstraZeneca have agreed to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical-inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)). Under the agreement, AstraZeneca will make a one-time $50-million upfront payment, and the companies will share both costs and profits. Based on current plans, approximately 65% of costs for the 2012–2014 period will be funded by AstraZeneca. Afterwards, the companies will split costs equally. Amgen will book sales globally and will retain a low single-digit royalty for brodalumab and a mid single-digit royalty for the rest of the portfolio, after which the companies will share profits equally. Read More
Advertisement:
Quantitative Determination of Genotoxic Impurities Using Xevo TQD
Xevo TQD is the only integrated system in its class that enables simultaneous acquisition of high quality quantitative and qualitative data from the widest range of experiments.
This application note demonstrates a rapid, simple and powerful approach to genotoxic impurity identification at the Threshold of Toxicological Concern (TTC) using the Xevo TQD when used in a qualitative manner with the ASAP Probe and product ion confirmation (PIC).  Learn More… |
Fujifilm Diosynth Biotechnologies has completed the first phase of a £3-million ($4.5 million) investment in new equipment and laboratories at its Billingham, United Kingdom, site. The investment includes a complete refurbishment of its microbial fermentation laboratory, which has been totally refitted, including eight new in-situ sterilizable 20-L Sartorius Stedim Biotech fermenters, and several Dasgip parallel benchtop high-throughput units. In addition, a new suite of R&D laboratories has been installed for process development work, with a corresponding increase in the company's R&D workforce by 50 to more than 150 in the last 12 months. Read More
Takeda Pharmaceutical has announced that its Corporate Strategy & Planning Department and Finance & Accounting Department will jointly be reorganized to form two new departments, named the Corporate Strategy Department and the Corporate Finance & Controlling Department, effective Apr. 1, 2012, with its newly announced heads reporting to the president & CEO directly. Read More
Advertisement:
INTERPHEX™ New York May 1-3, 2012 - Javits Convention Center - New York, NY INTERPHEX™ is the leading annual pharmaceutical and biopharmaceutical trade show. Key decision makers find the networking opportunities, products, services and information they need to ensure quality and maximize efficiency, agility, and flexibility that solve manufacturing and supply chain problems. Find out more at  http://www.interphex.com/AT. |
Teva Canada has finalized an agreement under which the CMO Halo Pharmaceutical will acquire Teva's Mirabel, Quebec, Canada, manufacturing facility. The transaction is subject to approval by the Competition Bureau, successful negotiation of manufacturing agreements between Teva Canada and Halo, and receipt of manufacturing permits from various authorities. The closing of this transaction is currently scheduled for June 30, 2012. Read More
Advertisement:
Podcast -  Process Validation for Sterile Manufacturing
Join William (JR) Humbert, the Validation Manager at Cook Pharmica, as he discusses the 2011 FDA Guidance for the Industry, Process Validation: General Principles and Practices, and the impact the guidance has for biotechnology and pharmaceutical companies performing sterile manufacturing process validation. |
Industry Briefs:
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Advertisement:
Risk Management in Sterile Manufacturing
LIVE WEBCAST:Thursday, April 12, 2012 from 2:00 PM - 3:00 PM EDT
Register Free at  http://www.pharmtech.com/dpt |
Do you have news to report on facility expansions, contracts, service agreements, mergers, acquisitions, or personnel appointments? Send press releases to [email protected] |
|
|
|
|
|
|
|
